Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m sulesomab - Immunomedics

Drug Profile

Tc 99m sulesomab - Immunomedics

Alternative Names: IMMU-MN3; ImmuRAID MN3 Tc 99m; LeukoScan

Latest Information Update: 15 Jul 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteomyelitis

Most Recent Events

  • 17 Jan 2005 Registered for Osteomyelitis diagnosis in Canada (IV)
  • 30 Jun 2003 Data from a media release have been added to the Musculoskeletal Disorders therapeutic trials section
  • 13 Jun 2002 Tc 99m sulesomab has been licensed to Teva-Tuteur in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top